Injectable Foam Dressing Conforms to Deep Traumatic Wounds and Inhibits Bacteria

Deep traumatic wounds can be difficult to manage because they often form irregular cavities that flat dressings cannot adequately fill. Blast injuries and other complex wounds also carry substantial risks of infection, tissue loss, amputation, and death, particularly in crisis settings where advanced hospital care may not be immediately available. To provide a more adaptable treatment option in these situations, AleSac has developed an injectable silicone foam prototype for complex wound care.

The wound foam technology originated from research at the Technical University of Denmark (DTU), and AleSac has developed a physical prototype based on that work. The system uses a caulking gun filled with a silicone compound that can be injected directly into a deep wound. Once the liquid comes into contact with the wound, it expands into a soft, moldable foam that fills the cavity and conforms to its shape.

The foam is designed to serve two key wound-management functions. First, it absorbs wound exudate, which can worsen the wound environment and may contain harmful bacteria. Second, it provides an antibacterial effect intended to inhibit bacterial growth, disrupt biofilm, and combat multidrug-resistant bacteria.

Laboratory testing has shown that AleSac’s antibacterial foam was effective against multidrug-resistant bacteria in less than 120 minutes. The technology is being developed for severe traumatic wounds, including blast injuries and other complex injuries in which rapid wound management may help preserve tissue. It may also have potential in settings where infection control is critical and access to advanced hospital care is delayed.

AleSac has been accepted into the U.S. medtech accelerator program BioLab CATALYST. Through the program, the company will receive specialist advice on European and U.S. regulatory requirements, including processes related to future U.S. Food and Drug Administration (FDA) approval. The program is part of the company’s plan to eventually commercialize the wound treatment in the U.S. market.

“We started with a simple question: Why do we treat deep wounds with flat products? Our technology is designed to fit the wound itself and create better conditions for managing complex wounds,” said Anne Ladegaard Skov, co-founder, professor and department head at DTU Chemical Engineering.

“This acceptance is a significant milestone for AleSac. It gives us access to both unique regulatory expertise and a strong international network of investors, both of which can support our ambition to bring a new and effective wound treatment to patients in the U.S. market,” added Skov.

Related Links
Technical University of Denmark